Pila Pharma: Initial results from the 13-week safety study
Research Note
2022-10-12
09:50
Redeye feels encouraged that the preclinical preparations of XEN-DIA keep progressing according to plan. We leave a short comment.
FE
Filip Einarsson
Disclosures and disclaimers